Fast Market Research recommends "Analgesics in France" from Euromonitor International, now available
[USPRwire, Tue Jan 05 2016] In 2015, analgesics recorded current value growth that was similar to the average for the review period. The category continued to face competition from prescription drugs. A large number of consumers continued to prefer to see a doctor in order to obtain a prescription and to purchase reimbursable analgesics. Despite efforts by the government to delist several types of analgesics over the review period, self-medication developed slowly due to high reimbursement rates. In addition, delays faced by manufacturers in obtaining authorisation for launching new products did not favour the category. Manufacturers preferred to invest in other categories that offered better margins, as the prices of traditional analgesics, such as aspirin and acetaminophen, are relatively low.
Full Report Details at
Analgesics is a concentrated category with the two leading players accounting for a combined value share of 52% in 2015. Sanofi led with a 30% value share, and the player continued to lead acetaminophen in 2015, which was thanks to the performance of Doliprane. This brand enjoys strong recognition and it is often asked for by consumers wishing to self-medicate, which supported a strong performance by Sanofi in 2015. Laboratoires UPSA followed with a 22% value share, which was mainly thanks to the performances of Dafalgan and Efferalgan. Both are alternative acetaminophen brands to Doliprane, and are offered in adults and children variants.
Strong lobbying has come from some grocery retailers, such as E Leclerc, for selling analgesics. Part of the industry had consequently been expecting the withdrawal of reimbursement for some medicines, notably acetaminophen; however, in 2015, the Minister of Health announced that health should continue to be primarily a responsibility of the state. This speech demonstrated that no drastic developments could be expected within analgesics in the short and medium term. Chemists/pharmacies are likely to maintain their monopoly in terms of sales of analgesics, and the level of reimbursement is unlikely to change.
Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in France with research from Euromonitor's team of in-country analysts.
Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.
If you're in the Analgesics industry in France, our research will save you time and money while empowering you to make informed, profitable decisions.
The?Analgesics in?France market research report includes:
* Analysis of key supply-side and demand trends
* Detailed segmentation of international and local products
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
You may also be interested in these related reports:
- Analgesics in South Korea
- Analgesics in Tunisia
- Analgesics in the United Arab Emirates
- Analgesics in Mexico
- Analgesics in Algeria